Cardiovascular function in acromegaly.

Even with modern treatment, acromegaly is associated with a 2- to 3-fold increase in mortality, mainly from vascular disease, which is probably a result of the long exposure of tissues to excess GH before diagnosis and treatment. There is accumulating evidence that effective treatment to lower serum GH levels to less than 1-2 ng/ml (glucose suppressed or random, respectively) and normalize IGF-I improves long-term outcome and survival. In addition to recognized cardiovascular risk factors of hypertension, type 2 diabetes mellitus, and dyslipidemia, there is accumulating evidence of specific structural and functional changes in the heart in acromegaly. Along with endothelial dysfunction, these changes may contribute to the increased mortality in this disease. There are specific structural changes in the myocardium with increased myocyte size and interstitial fibrosis of both ventricles. Left ventricular hypertrophy is common even in young patients with short duration of disease. Some of these structural changes can be reversed by effective treatment. Functionally, the main consequence of these changes is impaired left ventricular diastolic function, particularly when exercising, such that exercise tolerance is reduced. Diastolic function improves with treatment, but the effect on exercise tolerance is more variable, and more longitudinal data are required to assess the benefits. What scant data there are on rhythm changes suggest an increase in complex ventricular arrhythmias, possibly as a result of the disordered left ventricular architecture. The functional consequences of these changes are unclear, but they may provide a useful early marker for the ventricular remodeling that occurs in the acromegalic heart. Endothelial dysfunction, especially flow-mediated dilatation, is an early marker of atherosclerosis, and limited data imply that this is impaired in active acromegaly and can be improved with treatment. Similarly, early arterial structural changes, such as thickened intima media layer, appear more common in acromegalics, and there are hints that this may diminish with effective treatment, although more studies are required for a definite conclusion on this topic. In conclusion, impaired cardiac and endothelial structure and function in acromegaly are risk factors for vascular mortality and should be regarded as legitimate therapeutic targets in the overall management of this condition.

[1]  J. Hardy,et al.  Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly , 2003, Clinical endocrinology.

[2]  P. Chanson,et al.  Guidelines for acromegaly management. , 2002, The Journal of clinical endocrinology and metabolism.

[3]  P. Marzullo,et al.  Early vascular alterations in acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.

[4]  A. Neskovic,et al.  High output heart failure in patients with newly diagnosed acromegaly. , 2002, The American journal of medicine.

[5]  R. Erbel,et al.  Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy , 2002, Clinical endocrinology.

[6]  C. Mady,et al.  Treatment of acromegaly improves myocardial abnormalities. , 2002, American heart journal.

[7]  P. Marzullo,et al.  Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. , 2002, European journal of endocrinology.

[8]  R. Clayton,et al.  Endothelial dysfunction in endocrine disease , 2001, Trends in Endocrinology & Metabolism.

[9]  R Erbel,et al.  Occurrence of ventricular late potentials in patients with active acromegaly , 2001, Clinical endocrinology.

[10]  P. Robbins,et al.  Demonstration of Direct Effects of Growth Hormone on Neonatal Cardiomyocytes* , 2001, The Journal of Biological Chemistry.

[11]  Y. Saitoh,et al.  Characterization of premature atherosclerosis of carotid arteries in acromegalic patients , 2001, Clinical endocrinology.

[12]  P. Marzullo,et al.  Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly , 2001, Clinical endocrinology.

[13]  P. Marzullo,et al.  Growth hormone and the heart , 2001, Clinical endocrinology.

[14]  P. Chanson,et al.  Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction , 2000, Clinical endocrinology.

[15]  F. Casanueva,et al.  Criteria for cure of acromegaly: a consensus statement. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  B. Saul,et al.  Clinical significance of variability of ventricular late potentials detected before discharge in patients after myocardial infarction. , 2000, American heart journal.

[17]  P. Marzullo,et al.  Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  B. Biondi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Cardiovascular Effects of Short-Term Growth Hormone , 2022 .

[19]  M. Zamboni,et al.  Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity , 1999, International Journal of Obesity.

[20]  T. Anderson,et al.  Assessment and treatment of endothelial dysfunction in humans. , 1999, Journal of the American College of Cardiology.

[21]  M. Salvatore,et al.  Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. , 1999, The Journal of clinical endocrinology and metabolism.

[22]  F. Crea,et al.  Cell death in acromegalic cardiomyopathy. , 1999, Circulation.

[23]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[24]  L. Evans,et al.  Heterogeneous haemodynamics in acromegaly: evidence of endothelial dysfunction? * , 1998, Clinical endocrinology.

[25]  A. Simon,et al.  Decreased regional blood flow in patients with acromegaly , 1998, Clinical endocrinology.

[26]  P. Black,et al.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[27]  R. McNally,et al.  Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study , 1998 .

[28]  A. Gulino,et al.  Echocardiographic evidence for a direct effect of GH/IGF‐I hypersecretion on cardiac mass and function in young acromegalics , 1998, Clinical endocrinology.

[29]  S. Coppack,et al.  Endothelial Dysfunction: Cause of the Insulin Resistance Syndrome , 1997, Diabetes.

[30]  S. Melmed,et al.  New developments in the management of acromegaly , 1997 .

[31]  R. Clayton New developments in the management of acromegaly. Should we achieve absolute biochemical cure? , 1997, The Journal of endocrinology.

[32]  L. Poston,et al.  Oxidative Stress and Lipids in Diabetes: A Role in Endothelium Vasodilator Dysfunction? , 1996, Vascular Medicine.

[33]  A. Baron,et al.  Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. , 1996, The Journal of clinical investigation.

[34]  P. Douglas,et al.  Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. , 1996, Circulation.

[35]  G. Molino,et al.  Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. , 1996, Metabolism: clinical and experimental.

[36]  M. Radomski,et al.  Nitric oxide--biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. , 1995, Atherosclerosis.

[37]  P. Marzullo,et al.  Growth hormone and the heart , 2001, Endocrine Updates.

[38]  B. Biondi,et al.  Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. , 1994, The Journal of clinical endocrinology and metabolism.

[39]  P. Wrightson,et al.  Determinants of clinical outcome and survival in acromegaly , 1994, Clinical endocrinology.

[40]  R. Clayton,et al.  An audit of outcome of treatment in acromegaly. , 1993, The Quarterly journal of medicine.

[41]  R. Dullaart,et al.  Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients , 1992, European journal of clinical investigation.

[42]  R. Erbel,et al.  Arrhythmia profile in acromegaly. , 1992, European heart journal.

[43]  M. Komajda,et al.  Cardiac hypertrophy and function in asymptomatic acromegaly. , 1991, European heart journal.

[44]  J. Vane,et al.  Regulatory functions of the vascular endothelium. , 1990, The New England journal of medicine.

[45]  E. Raftery,et al.  Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. , 1989, British heart journal.

[46]  B. Sherman,et al.  Variability in the quantitation of circulating growth hormone using commercial immunoassays. , 1989, The Journal of clinical endocrinology and metabolism.

[47]  B. Bengtsson,et al.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. , 2009, Acta medica Scandinavica.

[48]  R. Emanuel,et al.  Acromegalic heart disease: influence of treatment of the acromegaly on the heart. , 1987, The Quarterly journal of medicine.

[49]  J. Lie,et al.  Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. , 1980, American heart journal.

[50]  D. Appleton,et al.  EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION , 1980, Clinical endocrinology.

[51]  C. Lowy,et al.  MORTALITY IN ACROMEGALY1 , 1970 .

[52]  C. Lowy,et al.  Mortality in acromegaly. , 1970, The Quarterly journal of medicine.

[53]  C. Courville,et al.  THE HEART IN ACROMEGALY , 1938 .